97 related articles for article (PubMed ID: 876133)
1. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
Buckley CE; White DH; Seigler HF
Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
3. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
Wile AG; Sparks FC; Morton DL
Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
[TBL] [Abstract][Full Text] [Related]
4. Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton D; Eilber FR; Malmgren RA; Wood WC
Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
[TBL] [Abstract][Full Text] [Related]
5. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
6. Immunological monitoring of melanoma patients on BCG immunotherapy. I. Enzyme-linked immunosorbent assay of human sera after BCG-treatment.
Kovatchev D; Kolushky V; Engibarov A
Neoplasma; 1984; 31(4):453-8. PubMed ID: 6472516
[TBL] [Abstract][Full Text] [Related]
7. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
8. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
10. Immunological changes in cancer patients receiving BCG.
Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterial antibodies after tuberculin testing, BCG- vaccination, BCG-immunotherapy and against cross-reacting antigens in a solid-phase radioimmunoassay.
Mauch H; Brehmer W
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Mar; 251(3):380-8. PubMed ID: 6805156
[TBL] [Abstract][Full Text] [Related]
13. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
Thatcher N; Crowther D
Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
[TBL] [Abstract][Full Text] [Related]
14. Defence systems of the body, immunosuppression and immunotherapy.
James DG
J R Nav Med Serv; 1976; 62(2):60-72. PubMed ID: 787517
[No Abstract] [Full Text] [Related]
15. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
16. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
[TBL] [Abstract][Full Text] [Related]
17. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
18. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
19. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
20. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
